Redsense Medical AB will participate in the virtual investor meet Aktiedagen Digitalt. Patrik Byhmer, CEO, will present the company and its operations at 10:30 a.m. on Monday, September 21, 2020. The presentation will be held in Swedish. To view the list of speakers and find more information about the event, please visit https://www.aktiespararna.se/aktiviteter/aktiedagen-digitalt-21-september-2020. “We welcome…
Read moreAs previously disclosed on October 7, 2019, Redsense Medical AB initiated an innovation project in artificial intelligence (AI). This project has now been concluded. “Machine learning (ML) is a powerful and cost-efficient method for establishing the relevant parameters of a noisy signal, and a further development of such concepts within the context of wound care…
Read moreRedsense Medical AB has received an order for six Redsense Alarms from the CHRISTUS St. Michael Health System in the U.S. The devices will be used in the hospital´s Acute Program, where the patient-to-nurse ratio is 2:1, to ensure patient and staff safety. The hospital, established in 1916, is affiliated with the Cleveland Clinic and serves the four-states region of…
Read moreRedsense Medical AB has previously submitted a renewal application to conduct a follow up study on a prototype of the Company’s accessory product Redsense Clamp, which enables automatic stop of blood flow independent of the dialysis machine in use. This application has now been approved by the Research Ethics Board of the University Health Network,…
Read moreCenters for Medicare & Medicaid Services (CMS) issued a new proposed rule to update payment policies and rates on or after January 1, 2021. The rule builds on the Advancing American Kidney Health Initiative Executive Order for home dialysis and would increase the bundled dialysis payment, which in turn would expand a financial incentive to encourage innovation…
Read moreTwo members of Redsense Medical’s senior sales management have exercised their rights to buy shares in the Company under a personal incentive programme adopted in 2016 through an agreement between them and Redsense Medical’s CEO, Patrik Byhmer. Brendan Kane, Redsense’s U.S. Director of Sales, and Sebastien Bollue, Redsense’s Director of Commercial Operations globally and responsible…
Read moreRedsense Medical AB announces today that an evaluation programme is launching in the Netherlands to test a new version of the Redsense Alarm, with additional functionality that has been developed in response to clinical experiences – a direct connection for the unit into the nurse call system of the clinic. The evaluation will comprise 100-150…
Read moreRedsense Medical announces today that the company has secured its largest single order ever. The record order, received from one of the company’s US distributors, is worth MSEK 3.1 and will bring Redsense’s sales for the second quarter to a new record high, surpassing Q1 2020. “We are proud and excited to receive this landmark…
Read moreMunson Healthcare, northern Michigan’s largest and leading health care system, has decided to adopt the Redsense system for use in its home dialysis practices. Munson Healthcare is a system of nine community hospitals located throughout northern Michigan and serves a region with more than 500,000 residents.
Read moreSanderling Renal Services, headquartered in Nashville, Tennessee, has purchased 10 Redsense devices for one of their Nashville facilities. Sanderling is a US dialysis provider with a nation-wide network of clinics. “Sanderling Renal Services has a focus on high quality patient care and pioneering use of innovative equipment and technology,” says Brendan Kane, US Director of…
Read moreOn 26 May 2020, the same day as the original date of application of the EU’s new Medical Device Regulation (MDR), Redsense Medical became one of the first companies to achieve compliance with the new regulations as the Company obtained its confirmation of registration. The revised legal framework for medical devices in the EU was…
Read moreOxford University Hospitals (OUH), one of the largest hospitals in Europe and a foundation trust within the National Health Service (NHS), the public healthcare system of the UK, has now included Redsense in their safety guidelines and in the patient information directed to patients on dialysis treatment about the danger of venous needle dislodgement and how to…
Read moreThe COVID-19 pandemic has prompted governments all over Europe to implement far-reaching restrictions and lockdowns in an effort to curb the outbreak and mitigate its toll on society. As the various sanctions now cautiously and gradually are being relaxed and lifted across different countries and the wheels of the economy slowly are put in motion,…
Read moreThe Board of Directors of Redsense Medical AB has resolved to postpone the Annual General Meeting of shareholders. The event will be held on Monday, 22 June 2020, 16:30, instead of 4 May 2020 as previously disclosed. Further information about the meeting will be announced at a later time. The publication dates for financial information are…
Read moreFurther to recent developments of the ongoing COVID-19 outbreak on Redsense Medical AB’s markets, the Company announces the following statement regarding the Company’s current operations. Thanks to a well established domestic organization in the US, the Company is not expecting any supply disruptions from the US travel ban, and the COVID-19 outbreak is not expected…
Read moreRedsense Medical AB announces the receipt of a Final Notice with regard to the patent application for the second invention related to the Company’s smart wound care technology for optical measuring of blood and exudate. The Final Notice expresses PRV’s intent to approve the application under the condition that certain modifications are made no later…
Read moreRedsense Medical AB announces that the Company’s PCT application for a first smart wound care invention now is published.
Read moreIn the coming weeks, Redsense Medical AB will present the company and its operations at two occasions. The first presentation will be held on Wednesday March 4, 2020 at Life Science-dagen in Gothenburg, where member of the board and major shareholder Susanne Olausson will give a background to the company and detail its current position in relation to the…
Read moreFollowing the turn of the year, Redsense Medical has during the first days of January received an influx of new orders to a combined value of more than MSEK 1.5; these new orders bring the Company’s current total order book value up to approximately MSEK 2. In the last quarters of 2019, the Company’s order backlog increased significantly as market…
Read moreThe Board of Directors of Redsense Medical AB (publ.) has resolved, in accordance with the authorization given by the Annual General Meeting on 6 May 2019, to increase the Company’s share capital with SEK 36,589.60 through a directed new share issue.
Read moreRedsense Medical announces that the Company is reviewing and optimizing its supply chain in order to increase production capacity and ensure efficient and speedy deliveries ahead. These efforts are in response to a significant increase of the Company’s order backlog in the last quarters, due to rising demand from the market. ”The backlog has grown…
Read moreRedsense Medical has signed an agreement with Ann-Marie Eriksson, who will be the Company's new Chief Technology Officer. When Ann-Marie joins the Company, she will be responsible for leading the R&D projects, a key task as the Company continues to develop its blood loss detection technology into a comprehensivesolution for smart wound care adapted to meet thedemands of the future.…
Read moreThe Board of Directors of Redsense Medical AB (publ.) has resolved, in accordance with the authorization given by the Annual General Meeting on 6 May 2019, to increase the Company’s share capital with SEK 30,514.90 through a directed new share issue.
Read moreRedsense Medical announces today thatit has received theInternational Search Report and Written Opinion issued by the International Searching Authority regarding its international application no. PCT/SE2019/050721, filed August 2019 under the Patent Cooperation Treaty. The opinion was completed in October 2019. All claims under the Opinion have been found to be novel and have “inventive step” (i.e., to be non-obvious). The invention is…
Read moreRedsense Medical’s commercial momentum and sales are continuing in Q4 and the company already booked a large order of blood leakage alarms and sensors from distribution partner Metro Medical Supply Inc. Redsense Medical now starts Q4 with an order worth 2 MSEK, compared to a result of 1,8 MSEK for the whole Q4 period the…
Read moreRedsense Medical AB has received a grant of SEK 500,000 from Vinnova, Sweden's government agency for innovation,to carry out aninnovation project in artificial intelligence. The aim of the project is to develop an AI-driven software, which will be employed in a smart monitoring system for wound care. The grant is awarded as part of the agency’s new effort…
Read moreRedsense Medical announces a new initiative aimed at facilitating the reporting process for Venous Needle Dislodgement (VND). The project, undertaken by the EDTNA/ERCA and supported by an Educational Grant by Redsense, includes the creation of an online checklist and a reporting tool.
Read moreThe Redsense technology is becoming available to more patients in the US, as several leading dialysis providers have decided to incorporate the device in their clinical practice. The Redsense device is now introduced at the facilities of the Rogosin Institute, long recognized as one of the premier centers in the US for kidney disease diagnosis…
Read moreRedsense Medical has submitted a patent application for a ‘method and device for monitoring a measurement object’. The application derives from the company’s work on its previously granted Swedish patent for smart bandages – ‘A Device for measuring a property of a measurement object by luminescence’ – announced earlier this year. The filed patent is a…
Read moreFollowing a Q2 which marked a new record level for the company, Redsense has during the months of July and August 2019 already received orders from the US with a total value surpassing MSEK 4. Larger US providers have publically communicated their intention to continue to improve and increase their operations in home hemodialysis. This is also…
Read moreRedsense medical has submitted a PCT application based on their Swedish patent for smart bandage - ‘A Device for measuring a property of a measurement object by luminescence’. The Swedish patent approval has been announced earlier this year.
Read moreRedsense Medical is starting Q3 with sound commercial momentum and a strong sales level. Redsense Medical announces that Metro Medical Supply Inc., distribution Partner of Redsense Medical based in Nashville, USA, have booked an order of blood leakage alarms to a value of MSEK 1,5. The order is significant, and it sheds light on a…
Read moreRedsense Medical has signed a collaboration agreement with Physidia, a French dialysis company focusing on the home hemodialysis market. The collaboration includes a direct connection with the Redsense blood leakage alarm with Physidia’s S3 dialysis monitor.
Read moreRedsense Medical announces that a large international dialysis care provider will initiate a soft rollout of the Redsense blood leakage alarm, making it available to selected acute care hospitals with special needs. The decision was made following a successful evaluation at multiple locations.
Read moreRedsense Medical announces that the company will receive a patent approval in Sweden for the innovative smart wound care technology that was presented in November, 2018. The patent covers optical sensor measuring and will be valid until 2038.
Read moreRedsense Medical announces that the company has started the development of a prototype with fully functional optical measuring based on the innovative, smart wound technology that was presented in November 2018. The prototype is expected to be ready in Q2 2019.
Read moreRedsense Medical has received a second order from Dirinco, the company’s distributor in the Netherlands, valued ca 200 KSEK, with the possibility to scale up. As announced in October 2018, the evaluation of the company’s blood leakage alarm at a reference clinic is now extended to also include nighttime dialysis treatments.
Read moreToday, Redsense Medical announces that the company has developed a new technology platform for smart optical measuring of substances such as blood and exudate, by using for example temperature and pressure in bandages or adhesive plasters. Discussions have been initiated with global wound care companies, and a first patent application has been filed.
Read moreRedsense Medical announces the completion of a clinical study with Redsense Clamp, an accessory to the company’s blood leakage alarm enabling automatic stop of the blood flow independent of the dialysis machine, by the University Health Network in Toronto, Canada. The results from the study will be published in two separate scientific articles.
Read moreRedsense Medical AB (publ) announces that a first order valued at 150 KSEK has been received from the company’s Italian business partner Spindial based on the large Consip tender where Spindial was declared one of five winners. The deliveries are now starting and will continue for five years.
Read moreRedsense Medical announces that Dirinco, the company’s distribution partner in the Netherlands, concluded a successful initial evaluation of the Redsense blood leakage alarm system directly connected to a Nikkiso DBB-EXA dialysis machine.
Read moreRedsense Medical has signed a distribution agreement for the Netherlands with Dirinco that builds upon the letter of intent signed in September 2017. Dirinco offers the Redsense alarm system together with hemodialysis machines from Redsense collaboration partners Nikkiso and NxStage.
Read moreRedsense Medical has signed a distribution agreement for Italy with its business partner Spindial, that was selected as one of the winners in a public procurement in Italy last autumn for over 3 million dialysis treatments. A first order is expected early in the third quarter.
Read moreRedsense Medical has signed a distribution agreement for Spain with the company Palex Medical. A first order for the company’s blood loss alarm is expected in the coming weeks so that the system can be evaluated with Spanish health care professionals. The company also holds the distribution rights for directly compatible hemodialysis machines from Redsense’s…
Read moreRedsense Medical has received market approval for its blood loss alarm in Singapore. An order from the company’s distributor Transmedic is expected in Q3 2018 for the planned evaluation at Singapore General Hospital.
Read moreRedsense Medical har erhållit marknadsgodkännande för bolagets blodläckagealarm i Singapore. En order från bolagets distributör Transmedic väntas under Q3 2018 för användning under den planerade utvärderingen vid Singapore General Hospital.
Read moreRedsense Medical has signed a collaboration agreement with University Health Network in Toronto, Canada, to conduct a study with Redsense Clamp, an accessory to the company’s alarm system that can automatically stop the blood flow when blood leakage is detected, independent from the dialysis machine. The study includes home dialysis patients and will be conducted…
Read moreRedsense Medical announces that the company’s blood leakage alarm is in use at three of the five largest dialysis care providers in the USA: Fresenius, DaVita and American Renal. The alarm is also used at three of the top five-ranked hospitals in nephrology: Mayo Clinic, Cleveland Clinic and New York Presbyterian Hospital.
Read moreRedsense Medical has signed a distribution agreement for Singapore with the Asian distributor Transmedic. An evaluation of the company’s blood leakage alarm for used in connection with hemodialysis is expected to be initiated in Q1 2018 at Singapore’s largest hospital, Singapore General Hospital.
Read moreRedsense Medical announces that University Hospital Crosshouse in Kilmarnock, Scotland, will be first in the world to install Redsense blood leakage alarms that can also shut off the blood flow automatically in case of a blood leakage. Presently, this functionality demands that the dialysis machine is equipped with an interface in accordance with an international…
Read moreRedsense Medical has signed a distribution agreement for Estonia, Latvia and Lithuania with the company Sormedica, a part of the Interlux group. The company also holds the distribution rights for directly compatible hemodialysis machines from Redsense’s collaboration partner Nikkiso. A first order is expected by the end of the year.
Read moreRedsense Medical AB (publ) announces that the result of the public procurement in Italy, where its partner Spindial was declared as one of the winners, are now final after a judicial appeal process. The parties will now sign the final agreement. The first order based on the contract is expected during the first quarter of…
Read moreRedsense Medical has signed a distribution agreement for Belgium with Medicole BVBA, a company that also holds the distribution rights for directly compatible hemodialysis machines from Redsense’s collaboration partner Nikkiso. A first order worth approximately 0,1 MSEK is expected soon.
Read moreRedsense Medical has signed a letter of intent and is finalizing a distribution agreement with Netherland-based Dirinco covering the Netherlands, Belgium and Luxembourg. The distributor will offer the company's alarm system together with hemodialysis machines from Redsense collaboration partners Nikkiso and NxStage. The distributor has already placed a first purchase order for Redsense systems. The…
Read moreRedsense Medical has signed a distribution agreement with Hemotech in France, a market with around 46 000 dialysis patients. The distributor will sell the company´s alarm system, used for monitoring and minimizing blood leakage, together with dialysis machines from Nikkiso that can be connected directly to the alarm system for substantially improved patient security.
Read moreRedsense Medical has signed an agreement to sell the company's alarm system for detecting and minimizing blood leakage with the distributor Theramed AG in Switzerland. The first shipment of the company's most advanced alarm units, that can connect directly to dialysis machines, has already been sent to the distributor.
Read moreRedsense Medical is finalizing an agreement to sell the company's alarm system for detection of blood leakage with Theramed AG in Switzerland, who is also distributor of dialysis machines that can connect directly to Redsense Medical´s alarm system for increased functionality. Theramed has already published a customer magazine where Redsense is presented.
Read moreRedsense Medical has signed an agreement to distribute the company's Redsense system in Iran with local distributor Arena Darman Hegmataneh, and the first orders are expected during 2017. The agreement is an important step towards establishing the company in the Middle East. Iran invests heavily in the healthcare sector and has a dialysis market three…
Read more